FDG PET-CT for Lymphoma Radiotherapy Planning Version 1.3

Not Applicable

• Conditions: Improve the Radiotherapy Planning Process

• Registration Number: NCT01999998
• Lead Sponsor: The Leeds Teaching Hospitals NHS Trust

Brief Summary

Chemotherapy followed by radiotherapy is used to treat early stage lymphomas with excellent cure rates. However, a significant proportion of these patients develop cancers and heart diseases years later as a result of the radiotherapy. Therefore, there is a move to reduce radiation exposure without compromising cure rates. Radiotherapy is planned using a CT scan taken following chemotherapy when many of the original sites of the lymphoma are no longer visible using a CT scan taken following chemotherapy when many of the original sites of the lymphoma are no longer visible.

In order to safely minimise the volume treated with radiotherapy it is necessary to accurately reconstruct the extent of the lymphoma prior to chemotherapy on this 'planning' CT scan. A PETCT prior to chemotherapy is the best way of demonstrating the original extent of the lymphoma, but is taken in a different position to the radiotherapy treatment position. This aim of this study is to explore whether a PETCT scan taken prior to chemotherapy in the radiotherapy treatment position, in conjunction with advanced software to combine this scan with the subsequent radiotherapy planning CT, can be used to more accurately identify the lymphoma target. The study aims to recruit up to 20 patients with early stage Hodgkin lymphoma or high grade nonHodgkin lymphoma. A routine staging PETCT will be followed at the same session by a PETCT in the radiotherapy treatment position appropriate radiotherapy immobilisation devices. Participation in the study will not affect treatment decisions or the radiotherapy planning process. The PETCT in the radiotherapy planning position will be made available to the treating clinicians. The process of planning radiotherapy will not be systematically altered by the study. The study is aimed at determining how to improve the radiotherapy planning process in the future, in the hope of a reducing in the long term side effects of treatment whilst retaining high cure rates.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-08
• Study First Submitted: 2013-11-20
• Study First Submitted QC: 2013-12-02
• Study First Posted: 2013-12-03
• Status Verified: 2015-05
• Last Update Submitted: 2015-05-18
• Last Update Posted: 2015-05-19
• Primary Completion: 2016-04

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Age ≥18
• WHO Performance status 02
• Histologically proven Hodgkin lymphoma or high grade nonHodgkin lymphoma
• Ann Arbor Stage I/II disease based upon clinical examination and any radiology investigations performed
• Clinical decision to proceed with sequential chemotherapy and radiotherapy if stage I/II disease is confirmed on subsequent 18FDGPETCT staging
• Residual disease in situ after biopsy
• Able to provide fully informed written consent
• Able to lie flat for 1 hour
• Not be pregnant or breast feeding. Female patients of childbearing potential must agree to use effective contraception, be surgically sterile, or be postmenopausal.

Exclusion Criteria

• Hypersensitivity to fluorine18 FDG
• Hypersensitivity to iodinated contrast media or Gadolinium
• Poorly controlled diabetes
• Acute renal failure or moderate renal impairment (estimated glomerular filtration rate < 30 mL/min)
• Uncontrolled pain
• Urinary incontinence
• Female patients must not be pregnant and if of child bearing age using adequate contraception
• Breast feeding
• Serious psychiatric comorbidity

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
PETCT scan taken prior to chemotherapy in the radiotherapy treatment position, in conjunction with advanced software to combine this scan with the subsequent radiotherapy planning CT, to more accurately identify the lymphoma target.	2 years

Trial Locations

Locations (1)

The Leeds Teaching Hospitals NHS Trust; 🇬🇧 Leeds, United Kingdom